NCT06767956 is a Phase 1, PHASE2 clinical trial of GOLCADOMIDE in Non Hodgkin Lymphoma, sponsored by University of Pittsburgh.

Who is sponsoring NCT06767956?

NCT06767956 is sponsored by University of Pittsburgh.

What drugs are being tested in NCT06767956?

Interventions in NCT06767956: GOLCADOMIDE, Nivolumab.

What condition does NCT06767956 study?

NCT06767956 studies Non Hodgkin Lymphoma.

Is NCT06767956 still recruiting?

NCT06767956 is currently withdrawn. Last updated 13 April 2026.

Last reviewed 2026-04-13 · How we verify

NCT06767956

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Withdrawn Phase 1, PHASE2 Last updated 13 April 2026

What this trial tests

Phase 1, PHASE2 trial testing GOLCADOMIDE in Non Hodgkin Lymphoma. Withdrawn.

Timeline

30 June 2025

Primary endpoint
30 April 2027

30 April 2028

Quick facts

Lead sponsor	University of Pittsburgh
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	30 June 2025
Primary completion	30 April 2027
Estimated completion	30 April 2028

Drugs / interventions tested

GOLCADOMIDE — full drug profile →
Nivolumab (nivolumab) — full drug profile →

Conditions studied

Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →

Sponsor

University of Pittsburgh

Who can join

18 and older, any sex, with Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this combined phase I/II, open label, single arm trial to study, the safety and efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refractory/residual disease, at or after 30 days of receiving chimeric antigen T-cell (CAR-T) therapy will be studied. A dose escalation phase will be followed by a dose expansion design.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy.
Wang H, Peng J, Li H, Lan Y, et al · · 2025 · cited 1× · PMID 41362701 · DOI 10.1002/mco2.70528

Verify or expand the search:

Other recruiting trials for Non Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting

Other University of Pittsburgh trials

Trials by the same sponsor.

NCT05601206 — Collaborative Care Intervention for Cancer Patients and Their Family Caregivers -LITE · NA · not yet recruiting
NCT06652815 — Cognition, Metacognition, and Stigma in Patients With Suicidal Ideation · not yet recruiting
NCT06474286 — Prucalopride for Cognitive Functioning in Schizophrenia · NA · not yet recruiting
NCT06488469 — Behavioural Problems and Cognition in Children With Hypoglycemia Unawareness in Type-1 Diabetes Mellitus · NA · not yet recruiting
NCT06652802 — Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06767956 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Pittsburgh
Last refreshed: 13 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06767956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing